Welcome to our dedicated page for Nektar Therapeutics news (Ticker: $NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nektar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nektar Therapeutics's position in the market.
Nektar Therapeutics reported their financial results for the first quarter of 2024, showing revenue of $21.6 million and a net loss of $36.8 million. The company's cash and investments were $326.0 million as of March 31, 2024, supporting operations until the third quarter of 2026. Progress was noted in their immunology and inflammation pipeline, with expectations for topline data from ongoing trials in 2025. Nektar also entered into a private placement financing agreement generating $30 million in gross proceeds.
Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.